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Since September 2016, all individuals in South Africa (SA) who are 
diagnosed as HIV-positive are immediately eligible for antiretroviral 
therapy (ART), regardless of CD4+ count. The current preferred 
first-line regimen is a fixed-dose combination tablet comprising three 
antiretroviral agents, including efavirenz (EFV).[1] Isoniazid (INH) is 
being increasingly used as tuberculosis (TB) prophylaxis, especially 
in HIV-positive individuals. This means that a high proportion of 
patients in SA are likely to be receiving concomitant EFV and INH 
therapy. We need to be aware of potential medication-related toxicity 
syndromes, especially in the context of polypharmacy.
EFV is a non-nucleoside reverse transcriptase inhibitor that 
is metabolised in the liver via the cytochrome p450 system, 
predominantly via CYP2B6.[2,3] It has a long half-life and is therefore 
prescribed as a once-daily dose of 600 mg. However, genetic 
differences in the pharmacokinetics of EFV are increasingly being 
recognised.[2]
EFV is well known to cause neuropsychiatric side-effects. These 
typically occur (in ~40% of cases) on initiation of the drug, but are 
usually mild and self-limiting within the first few weeks of exposure.[4]
A paediatric case series has described late-onset neurotoxicity 
associated with toxic EFV levels in the form of subacute ataxia in 
children treated with EFV-containing antiretroviral regimens for 
more than a year.[5] A more recent case series from Klerksdorp, SA,[6] 
described late-onset ataxia and encephalopathy in adult patients 
treated with EFV for a median of 2 years, in association with toxic 
plasma levels of the drug. These patients were all female with 
low body weight. Possible reasons proposed for susceptibility to 
EFV neurotoxicity included low body weight and polymorphism 
of the liver enzyme CYP2B6, which is known to result in slowed 
metabolism of the drug.[7] Two common polymorphisms in CYP2B6 
(516G>T and T983C) slow EFV metabolism and have been shown to 
occur with increased frequency in people with black African genetic 
ancestry.[3,8] These polymorphisms probably also play a role in the 
acute toxicity, and a case of new-onset psychosis following recent 
initiation of EFV has been described in the context of confirmed 
CYP2B6 516G>T polymorphism.[9]
INH is also metabolised in the liver via the cytochrome p450 
system. It inhibits the CYP2A6 enzyme. Although a small proportion 
of EFV is normally metabolised via this enzyme, this pathway may 
have a more important role in slow metabolisers with polymorphisms 
affecting CYP2B6. Concomitant INH use therefore affects plasma 
levels of EFV, especially in slow metabolisers. This has previously 
been noted in a pharmacodynamic study.[10,11] INH has also been 
independently associated with neuropsychiatric effects, occurring a 
median of 21 days after initiation of treatment.[12,13]
We have noted a recent increase in cases of EFV toxicity presenting 
to our tertiary neurology referral unit in the Western Cape Province, 
SA, over a relatively short period of time. All the cases occurred in 
the context of recent initiation of concomitant INH treatment. We 
therefore conducted a retrospective case record audit to describe 
these cases of late-onset EFV toxicity. We outline the clinical 
details (history and examination) and the results of investigations 
(laboratory results, electroencephalogram (EEG) findings, imaging 
and neuropsychological assessments), as well as outcomes after EFV 
was stopped. Comprehensive investigation is often undertaken in 
HIV-positive patients with impaired cognition and cerebellopathy, 
because the differential diagnosis is wide and some of these conditions 
could deteriorate significantly during the period in which EFV is 
withdrawn. Our main objectives are to highlight the probable role of 
concomitant use of INH in the development of this syndrome, and to 
suggest that where a diagnosis of EFV toxicity is strongly suspected, 
only limited work-up may be warranted.
Cases are defined as individuals presenting to the Groote Schuur 
Hospital neurology services with subacute neurological signs and 
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symptoms, confirmed toxic levels of EFV, and no other cause found 
for their presentation. The study was approved by the University of 
Cape Town Human Research Ethics Committee (ref. no. 603/2017).
Results
A typical case is that of a 37-year-old woman, originally from 
Lesotho, known to be HIV-positive (CD4+ count >500 cells/µL, viral 
load <20 copies/mL) who had been on ART (tenofovir/emtricitabine/
efavirenz) for 5 years. Concomitant INH prophylaxis was initiated 1 
month prior to symptom onset. She was admitted after developing 
subacute, progressive confusion and an unsteady gait over the course 
of 1 month.
On examination she appeared systemically well, but neurological 
examination confirmed that she was disorientated with psychomotor 
slowing, poor attention and blunted affect. Primitive reflexes were 
not elicited. The findings on cranial nerve examination were normal. 
Motor examination revealed normal tone and reflexes and full power. 
Sensation was normal. Co-ordination was abnormal, and she had 
horizontal- and upward-gaze nystagmus with left-sided dysmetria, 
bilateral intention tremor and abnormal heel-shin tests. Marked 
truncal ataxia with a broad-based ataxic gait was also noted.
On investigation, basic blood work-up including a CD4+/CD8+ 
ratio, thyroid-stimulating hormone (TSH) and vitamin B12 were 
normal. Syphilis serology (TPAb) was negative. Liver enzymes, 
a hepatitis screen, ammonia levels and an abdominal ultrasound 
scan were normal. Cerebrospinal fluid (CSF) analysis confirmed 
normal basic parameters, and  a cryptococcal latex antigen test, 
tuberculosis GeneXpert assay and JC virus polymerase chain 
reaction were negative. Neither computed tomography (CT) nor 
magnetic resonance imaging (MRI) of the brain revealed significant 
abnormalities. Two EEGs revealed generalised, high-amplitude, 
rhythmical, moderate (predominantly theta) slowing consistent with 
encephalopathy. Plasma EFV levels were toxic (>20 mg/L; normal 
therapeutic range 1 - 4 mg/L).
EFV and INH were immediately withdrawn (and EFV substituted 
with lopinavir/ritonavir (LPV/r). The patient also initially received high-
dose parenteral thiamine, with little effect. Initial clinical improvement 
was noted at the time of discharge (12 days after admission).
At follow-up 3 months later she showed marked improvement. 
She was living independently and seeking employment. Her affect 
was appropriate without psychomotor slowing. Montreal cognitive 
assessment screen was normal. Cerebellar examination was normal 
except for a subtle persisting intention tremor affecting her non-
dominant hand. A repeat EEG was normal.
A total of seven adult women with southern African ancestry 
presenting with subacute encephalopathy and cerebellar ataxia were 
identified between May 2017 and August 2017. All had been exposed 
to INH, either prophylactically or as part of TB treatment. Six of the 
seven women were HIV-positive with a suppressed viral load. One 
patient was HIV-negative but was prescribed both EFV-containing 
ART and INH at a community clinic following what appears to have 
been a false-positive HIV test.
The clinical picture was similar in all these cases, with marked 
truncal and gait ataxia and psychomotor slowing, resulting in 
severe functional impairment and inability to walk unaided. Four 
patients had nystagmus with abnormal smooth pursuit and saccadic 
overshoot. Two women exhibited additional mood and psychotic 
symptoms prior to the encephalopathic, ataxic presentation. One 
woman initially presented with psychosis and was admitted to the 
psychiatric ward before being referred for neurological assessment. 
The other woman initially presented with and was treated for 
depression as an outpatient (in hindsight this may have been a 
misdiagnosis of psychomotor slowing). Further characteristics of the 
included patients are summarised in Tables 1 and 2.
All the cases were investigated according to our neurology division 
practice. Blood tests included TSH, vitamin B12, TPAb, CD8+ count, 
liver function tests and ammonia levels. All the women had toxic 
plasma EFV levels (>20 mg/L). CSF was sampled in all cases and 
found to be normal (including JC virus/FTA-ABS/TB GeneXpert). 
CT and MRI brain imaging were performed in all cases. Two patients 
had non-contributory findings (one an old basal ganglia infarct 
and the other a left parietal FLAIR white-matter hyperintensity of 
undetermined significance on MRI).
EEG, performed in all cases, revealed distinct, moderately high 
amplitude, rhythmical, generalised (predominantly theta) slowing 
(except for one case in which the slowing was irregular). Formal 
neuropsychological assessments were performed in five cases. These 
yielded uniform findings of predominantly dysexecutive deficits 
and psychomotor slowing consistent with frontal lobe subcortical 
dysfunction.
All the women showed marked initial improvement in cerebellar 
and cognitive function a median of 14 days after EFV withdrawal.
Discussion
We have described a series of seven women on EFV-based ART 
with concomitant INH, who presented with a syndrome of subacute 
encephalopathy and cerebellopathy with toxic plasma EFV levels. 
The encephalopathy included disorientation and psychomotor 
retardation of varying severity, and psychosis in one case. Cerebellar 
dysfunction ranged from mild truncal ataxia to florid pan-cerebellar 
Table 1. Clinical characteristics of cases
Case 1 Case 2 Case 3 Case 4 Case 5 Case 6 Case 7
Cerebellar signs +++ ++ +++ + +++ + ++
Neuropsychiatric signs/symptoms +++ +++ +++ ++ +++ + +++
EEG generalised rhythmical slowing abnormality ++ ++ ++ ++ ++ (irregular) ++ ++
Days to initial improvement (median 14) 12 21 21 16 10 10 10
+ = mild; ++ = moderate; +++ = severe; EEG = electroencephalogram.
Table 2. Characteristics of the patients
Characteristics
Age (yr), median (IQR) 43 (36 - 47)
Weight (kg), median (IQR) 59 (55 - 62)
CD4+ (cells/µL), median (IQR) 353 (324 - 462)
Duration of ART (mo), median (IQR) 34 (17 - 48)
Duration of TB treatment before onset of 
symptoms (mo), median (IQR)
3.5 (2.75 - 4.25)
Duration of INH prophylaxis before onset of 
symptoms (mo), median (IQR)
6 (2 - 9)
IQR = interquartile range; ART = antiretroviral therapy; TB = tuberculosis; INH = 
isoniazid.
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dysfunction, including nystagmus. All 
the patients were virally suppressed with 
relatively well-preserved CD4+ counts (one 
patient was HIV-negative) and an otherwise 
negative diagnostic work-up. The patients all 
showed improvement within 14 days of EFV 
withdrawal, strengthening the hypothesis 
that drug toxicity was responsible.
Our patients were all women of southern 
African genetic ancestry with an age range of 
30 - 55 years. Patients described previously in 
a similar case series were also all women.[6] It 
is unclear whether the proposed mechanism 
of EFV toxicity (resulting from slow meta-
bolism of EFV due to polymorphisms of 
cytochrome CYP2B6)[2,7,14] may have a sex 
predilection, as previous studies assessing 
this have yielded conflicting results.[2,7,14] 
Some researchers suggest that non-Caucasian 
females are at high-risk for toxicity even after 
correcting for age and body weight.[14] Factors 
such as differences in compliance and health-
seeking behaviour between men and women 
may also play a role. There are almost twice 
as many women (compared with men) on 
ART in SA,[15] and women have higher rates 
of adherence to ART.[15,16]
Our patients all had considerable 
(asymptomatic) exposure to ART prior to 
presentation (although this varied widely 
from 5 months to 4 years), qualifying our 
defini tion of ‘late-onset’ EFV toxicity. Our 
patients had all recently been commenced 
on INH (either in the form of prophylaxis 
or as part of TB treatment) with an average 
of 3 months’ INH use prior to symptom 
onset. This implies a temporal relationship 
between INH commencement (in the 
context of EFV use) and onset of symptoms. 
While we did consider the possibility that 
INH toxicity might be the cause of the 
symptoms, we concluded that the EFV was 
more likely to be causative given the clinical 
improvement observed in two patients in 
whom INH was continued after withdrawal 
of EFV. Furthermore, limited studies of INH-
induced cerebral toxicity document earlier 
onset of symptoms (mean 21 days). [11,13] We 
were unable to measure INH blood levels in 
our patients.
Unlike a similar case series of EFV 
toxicity,[6] our patients had an average body 
weight of 55 kg, with none weighing less than 
40 kg. They all received the recommended 
dose of EFV (600 mg/d). A lower dose of 
EFV (400 mg/d) has been shown to be 
non-inferior to 600 mg/d in terms of viral 
suppression,[17] and it has been suggested 
that this lower dose may reduce the risk of 
toxicity in underweight individuals.
We are unable to comment on whether 
toxic EFV levels may be found in asymp-
tomatic individuals, as EFV levels are not 
routinely measured as part of therapeutic 
drug monitoring.[18]
Based on our observations, we have 
proposed an algorithm (Fig. 1) for the clini-
cal management of patients presenting with 
possible EFV-induced late-onset ataxia. It 
is important that systemic diseases first be 
excluded. Red flags of older age, low CD4+ 
count and pyrexia make EFV toxicity less 
likely, and an alternative diagnosis should 
be more actively sought. However, once 
systemic diseases have been excluded, 
and if both the CSF and CT brain scan 
are normal, we propose that it could be 
appropriate to wait for the results of the 
EFV levels and not investigate the patient 
further while the levels are pending. This 
would reduce the costs of investigation 
and unnecessary transfer of patients to 
higher-level care facilities. Once there is a 
suspicion of EFV toxicity, the drug should 
be discontinued immediately. Alternatives 
such as nevirapine, LPV/r or dolutegravir 
can be used, depending on the patient’s 
viral load and clinical profile, including the 
presence of comorbid TB.
EEG is not required to make the diagnosis, 
but is useful in cases where it is clinically 
difficult to distinguish encephalopathy from 
psychiatric disorders.
This is a report of only a few cases observed 
at a single neurology referral centre, and the 
conclusions that can be drawn are therefore 
limited. We were not able to determine INH 
levels or EFV metaboliser genotype. Our 
observations do, however, corroborate those 
described in a similar group of patients.[6] 
We would also like to highlight the likely 
role of INH in precipitating this syndrome, 
and in our experience low body weight is not 
a necessary factor. The findings from this 
report support consideration of the removal 
of EFV as first-line treatment for HIV in SA. 
In the interim, clinicians need to be aware 
of the potential for the development of this 
syndrome in patients on EFV, especially 
those concomitantly managed with INH.
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History
Clinical examination
Exclude systemic illness
• Contrasted CT brain
• LP
• EFV-containing ART ± INH
• Sub-acute onset
• Ataxia
• Encephalopathy
Consider checking:
• TPA, TSH 
• LFTs and ammonia
• Vitamin B12, thiamine 
RED FLAGS
• Age >60 yr
• CD4+ <200 cells/µL
• Pyrexia
• ?Men*
• EFV level
• Switch to non-EFV-containing ART
Consider: MRI brain, JCV, CD8+ count, 
malignancy screen, tertiary hospital referral
}
CT, LP abnormal
EFV toxicity less likely
No cause for presentation found
Patient clinically improves 
<2 weeks
Await EFV level; consider 
down-referral/discharge
EFV level non-toxic
Fig. 1. Algorithm for the clinical management of suspected EFV neurotoxicity. (EFV = efavirenz; ART = 
antiretroviral therapy; INH = isoniazid; TPA = treponemal antibodies; TSH = thyroid-stimulating 
hormone; LFTs = liver function tests; CT = computed tomography; LP = lumbar puncture; MRI = 
magnetic resonance imaging; JCV = JC virus polymerase chain reaction. *All previously described adult 
cases are women, although numbers are limited.)
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